Crohn's and Colitis Congress 2021

Smoking effect on colorectal neoplasia risk may vary by IBD type

Roshini Claire Anthony, 20210205180001

The impact of cigarette smoke exposure on the risk of colorectal neoplasia (CRN) in patients with inflammatory bowel disease (IBD) may differ according to IBD type, suggested results of a single-centre study presented at the recent Crohn’s and Colitis Congress 2021.

Pre-op biologics not tied to post-op infection in IBD

Roshini Claire Anthony, 20210202180001

In patients undergoing surgery for inflammatory bowel disease (IBD), presurgical exposure to biologics was not associated with an increased risk of post-surgical infectious complications or surgical site infections, according to a study presented at the recent Crohn’s and Colitis Congress 2021.

Ozanimod benefits UC by lowering inflammation markers in the gut

Pearl Toh, 20210128140010

One way the S1P* receptor modulator ozanimod reduces disease activity in patients with ulcerative colitis (UC) is by driving down biomarkers of intestinal inflammation such as faecal calprotectin (FCP) and faecal lactoferrin (FLF), according to the TOUCHSTONE study presented at the 2021 Crohn’s and Colitis Congress.

Anti-TNF exposure may increase BMI in children with Crohn’s disease

Elaine Soliven, 20210128042924

Exposure to anti-TNF therapy appears to be associated with an increased body mass index (BMI) z-score in paediatric patients with Crohn’s disease, according to a study presented at Crohn’s & Colitis Congress 2021.

Amiselimod exhibits favourable safety in healthy individuals

Audrey Abella, 20210127100000

Amiselimod, an oral selective sphingosine 1-phosphate (S1P) receptor modulator, demonstrated a favourable safety profile among healthy individuals, according to a phase I study presented at Crohn’s and Colitis 2021.

IBD in kids: A protracted course?

Pearl Toh, 20210126143000

While children with inflammatory bowel disease (IBD) see their conditions improve with biologic therapy, those with ulcerative colitis (UC) tend to have residual disease activity even after clinical remission, according to two separate studies presented at the 2021 Crohn’s and Colitis Congress.

Antibiotics improve disease activity in adults with Crohn’s disease

Audrey Abella, 20210126100000

A meta-analysis presented at Crohn’s and Colitis 2021 demonstrated reductions in disease activity among adults with Crohn’s disease (CD) who were taking antibiotics.